Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2025

Share-Based Payment Arrangement [Abstract]

Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model

The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted during the three months ended March 31, 2025 and 2024:

	Three Months Ended March 31, 2025		Three Months Ended March 31, 2024
Risk-free interest rate		—		5.0	%
Expected term (in years)		—		5.0
Expected volatility		—		110.5	%
Expected dividend yield		—		0	%

Schedule of Stock Option Activity

The following table summarizes option activity with service conditions under the 2021 Plan and the 2017 Plan:

	Options			Weighted Average Exercise Price		Weighted Average Contract Term (years)		Aggregate Intrinsic Value
Outstanding at January 1, 2025		3,961,525		$	27.27		6.4		—
Granted		—			—		—		—
Exercised		—			—		—		—
Forfeited		(20,388	)		—		—		—
Outstanding at March 31, 2025*		3,941,137		$	27.38		6.0	$	7,250
Exercisable at March 31, 2025		2,645,145		$	37.44		4.5	$	—

* Options outstanding at March 31, 2025, under the 2021 Plan and 2017 Plan were 2,548,641 and 1,437,496, respectively. Options outstanding at March 31, 2025 under the 2021 Plan include 45,000 awards with performance conditions (see below).

Schedule of Warrants Purchase Agreement

Tranche	Shares		Exercise Price		Vesting Conditions
1		600,000	$	3.00	50,000 warrants vest monthly from Feb 1, 2025, with the first 50,000 warrants vesting immediately upon execution.
2		200,000	$	5.00	Vest upon the closing of a specified transaction.
3		200,000	$	6.00	Vest upon the closing of the same transaction.
4		500,000	$	12.00	Vest ratably over 12 months from May 19, 2025.
		1,500,000

Schedule of Activity Related to RSU Stock-Based Payment Awards

The following table summarizes activity related to RSU stock-based payment awards under the 2021 Plan:

	Number of Shares			Weighted Average Grant Date Fair Value
Outstanding at January 1, 2025		659,439		$	9.29
Granted		78,802		$	2.17
Released		(145,531	)	$	11.15
Forfeited/Expired		(10,878	)	$	17.03
Outstanding at March 31, 2025		581,832		$	7.71

Schedule of Stock-based Compensation Expense

The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:

	Three Months Ended March 31,
	2025		2024
Cost of revenues	$	63	$	106
Research and development		188		376
Selling, general and administrative		2,386		2,484
	$	2,637	$	2,966